The application of cells as pharmacological active substance has the purpose to repair, replace or recover the biological function of damaged tissue or organs. Cell therapy is an alternative for the treatment of both high prevalent chronic and rare diseases including immune 1 and cardiovascular diseases 2 , diabetes and their complications [3] [4] [5] [6] , neurodegenerative disorders 7 , inflammatory diseases such as Crohn's disease 8 , musculoskeletal diseases 9 , cancer 10 , etc.
Development of new medicines for the treatment of untreated disease aims to improve the patient's quality of life with new and specific therapies either addressed to the right target thus minimizing side effects or using new strategies and mechanisms of action which open new therapeutic avenues. In this context Europe has pioneered the development of advanced therapies; however most of the preclinical and clinical research is investigator-driven and less-frequently involving spin-offs and small biotech companies. Academic institutions and small and medium enterprises are not so familiar with regulatory issues as conventional pharmaceutical industry. In this manuscript we sCTMP have a specific regulation to harmonize legal framework and to promote research in this field.
This review describes and discusses the different stages in the development of a sCTMP, and both regulatory and practical requirements, from a European perspective.
REGULATORY AGENCIES
The three most important regulatory agencies that regulate the development of a of Pharmaceuticals for Human Use (ICH). Its main mission is to achieve management in the technical guidelines on the quality, safety and efficacy of new medicines 16 (Table   1 ). This organization brings together regulatory authorities, pharmaceutical industry and scientific experts from the United States, Japan and Europe.
Regulatory agencies also review the indications for use, content of the package leaflet, dosage, side effects, warnings and contraindications. Finally, they also ensure postregulatory Pharmacovigilance.
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European Medicines Agency (EMA)
EMA is a decentralized agency of the EU located in London (www.ema.eu). Its main responsibility is the protection and promotion of human and animal health, through the evaluation and supervision of medicines for human and veterinary use opinion on the quality, safety, and efficacy of a product for the final approval each ATMP marketing authorization application submitted to the EMA, before the CHMP adopts the final opinion on the medicine concerned. CAT offers a query system for the classification of ATMP. This procedure is optional, free of charge and may take place at any stage of the development of a sCTMP or any ATMP in advance of applying for a marketing authorization 18, 19 . CAT is involved in the certification of quality and/or nonclinical data, in the development of scientific guidelines and reflection papers and in regulatory procedures and scientific articles. Regulatory aspects for cell-based therapy medicinal products will be described in this paper in more detail.
Food and Drug Administration (FDA)
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Gene Therapy Medicinal Products (GTMP)
GTMP is defined as biological medicinal product containing an active substance which contains or consists of a recombinant nucleic acid used in, or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence 12, 14 . Its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence. GTMP shall not include vaccines against infectious diseases.
Tissue-engineered Products (TEP)
TEP are defined as a product that contains or consists of engineered cells or tissues used 
Combined Advanced Therapy Products (CATP)
CATP are products that incorporating as an integral part of the product, one or more medical devices or one or more active implantable medical devices. These products must contain viable cells or tissues, or its cellular or tissue part containing non-viable cells or tissues must be liable to act upon the human body with action that can be considered as primary to that of the devices referred to . National agencies are currently developing rules for hospital exemption with quality requirements similar to those applied by EMA. 
Experimental Observations
At this stage of development, experimental observations focused in basic laboratory research should determine the active (either differentiated progenitor or stem cells) and establish a tentative mechanism of action of the sCTMP to be developed. 
Pre-clinical Research
Preclinical development of a sCTMP refers to the set of studies on efficacy and safety of the active substance (cells) to be performed in biological systems distinct to the human that may give substantial information to address a Phase I-IIa pilot study. These may include in-vitro work with cellular models, preclinical experiments using animal cells in animal models and preclinical work using human cells in immunocompromised mice 43 . Although there are no perfect models that mimic the human disease, these approaches may provide enough information for ethical committees and regulatory agencies to decide for further development on the basis of the proper balance between risk and benefit for a specific situation.
The selection of animal models and species should be scientifically justified. . An effort should be made to introduce new tests that respond to these questions when using cells as medicines.
GLP are a set of principles that provides a framework within which laboratory studies are planned, performed, monitored, recorded, reported, and archived to ensure the reliability of data generated within a compliant laboratory 47 . A key feature of GLP is the generation of quality-control methods and data management within the cell culture laboratory 48 . GLP principles were set by the Organization for Economic Co-operation and Development (OECD). This organization has established the Mutual Acceptance of Data system in OECD member countries for the mutual acceptance of non-clinical safety study data 49 . For purposes of assessment and other uses related to the protection The OECD has issued a series of recommendations for compliance with the GLP.
These guidelines focus on the assessment of chemicals for very different applications, and also apply to medicines.
Clinical Research (and follow-up)
Clinical trials can be classified according to their purpose, phase I, phase II, phase III and Phase IV.
Clinical trials in Phase I are the first step in investigating a substance or new drug in humans. They are based to evaluate its safety, determine a safe dosage range, and identify side effects. This phase provides the approximate profile of safety and tolerance of the product. In advanced therapies would be a safety and feasibility study on patients. stage is to study the detection of long-term side effects, and possible effects of drug on the disease itself or studies of morbidity and mortality (Fig 1) .
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Manufacturing cell-based medicinal products
Technical requirements for sCTMP are based primarily on quality, safety and efficacy aspects. In contrast to traditional medicines, sCTMP have different and more specific characteristics. The risks analysis of the whole manufacturing process, the quality of manufacturing aspects and non-clinical and clinical development are aspects that should be taken into account when manufacturing a sCTMP 35 . . Therefore requirements for installations, staff, equipment, documentation, production, quality control, batch release, labeling, etc should be manufactured and checked in compliance with the requirements of GMP guidelines.
In practical terms these standards are described in EudraLex-Volume 4 GMP guidelines, The manufacturing process of a sCTMP for clinical use must be consistent and reproducible providing sufficient quality to the final product for patient safety. GMP applies to both production and quality control of the medicinal product. These guidelines ensure that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and according to the requirements of the product specification 59 .
Concerning quality control requirements it is important to check that the active substance of sCTMP is viable, so at the end of the process the final product for the patient, should not include terminal sterilization, purification steps and/or viral removal.
Therefore, the quality of the starting materials derived from animal or human origin should be analyzed. These materials comprise excipients and the donor of biological sample for the active substance. The quality criteria required by the European regulation for the characterization of the final product requires considerations such as, the identity of the cellular and non-cellular components; cell purity; impurities of product or related process; impurities as adventitious agents; potency and tumourigenicity
35
.
The manufacturing process of sCTMP should be carefully designed and validated to ensure product consistency and repeatability of the cell culture process. These products are highly heterogeneous due to their origin, starting material, degree of in vitro manipulation and manufacturing process 60 . . Thorough study of each process involved in the manufacture of a sCTMP should be made to ensure their safety in terms of quality.
Authorization, Registration and Marketing
The evaluation of the medicines for their authorization and commercialization is There three procedures to approve new medicinal products: the centralized procedure, generating a single marketing authorization valid throughout the EU, the decentralized procedure, in which the application is submitted to member states selected by the applicant and mutual recognition procedure, when the reference member state has already issued a marketing authorization. However, the centralized authorization procedure is compulsory for medicinal products manufactured by biotechnological methods and for advanced therapy medicinal products such as sCTMP.
The CAT is involved in all scientific advice on ATMPs and in the regulatory procedures of the classification and the certification procedures. CAT is responsible for the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 The marketing authorization is valid for five years and may be renewed. Once it has been renewed, it is valid indefinitely, unless the Commission chooses not to validate again for another five years. The approval decision will be taken based on the scientific criteria of quality, safety and efficacy in evaluation. These three criteria allow evaluating the risk-benefit balance of all medicines.
On the other hand, in order to give micro, small and medium-sized enterprises, EMA 
Post-authorization
Once the marketing authorization is requested and approved, EMA may request postauthorization studies, the authorization may be conditionally granted. Post authorization studies focus on pharmacovigilance; it is the science for the assessment, awareness and prevention of any side effects or possible adverse reactions associated with medicines. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Table 2) .
The development and manufacture of conventional medicines is performed by physical and chemical techniques with consistency and robustness. However, sCTMP development is a technique that still far to reach such strength. sCTMP should take into account the variability of the production process, the risk of exogenous contamination (microbiological, viral….)and variability of quality control techniques. Since active principals are active substances and not chemical compounds.
The European framework for the development of sCTMP aims to provide an increased international competitiveness of these products, the European regulation in the field of advanced therapies ensure that all patients receive drug treatment quality.
We anticipate that a deeper knowledge of regulatory issues among clinical investigators and small biotech enterprise will expand this field that holds the promise for so far untreatable diseases.
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CATEGORY CODE APLICATIONS
QUALITY Q
Concerning the stability studies, the definition of relevant limits for impurities testing and a focus on product quality SEGURITY S Guidelines for potential hazards such as carcinogenicity, genotoxicity and reproductive toxicity.
EFICACY E
For the design, development, safety and reporting of clinical trials. There are also guidelines for medicinal products derived from biotechnology processes, use of pharmacogenetics and genomic techniques for the production of more specific drugs.
MULTIDISCIPLINARY M
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